Vanta Bioscience
add_icon

Vanta Bioscience

18.19
-0.01
(-0.05%)
Market Cap
12.89 Cr
PE Ratio
-0.97
Volume
9,000.00
Day High - Low
18.19 - 18.19
52W High-Low
31.33 - 14.71
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
12.89 Cr
EPS
-7.56
PE Ratio
-0.97
PB Ratio
0.90
Book Value
20.28
EBITDA
-4.10
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
-351.27
Debt to Equity
5.11
Forecast For
Actual

Company News

View All News
Caret
neutral
Vanta Bioscience Limited submitted its quarterly compliance certificate under SEBI regulations for Q4FY26, with RTA confirming non-applicability due to fully demat shareholding.
neutral
Vanta Bioscience Limited responds to BSE's inquiry on price movement, stating compliance with disclosure norms and attributing share price changes to market forces.
positive
Vanta Bioscience Limited announced the appointment of Ms. Pooja Kothari as Company Secretary and Compliance Officer effective January 30, 2026, following board approval.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
445.00
#1 17,930.80
49.95
#1 3,714.20
3.77
#1 496
-88.56
59.27
488.00
11,751.43
#1 26.49
2,946.50
10.53
407
-6.20
54.54
212.77
4,935.24
-20.23
17.60
-46.34
-161
-160.61
80.86
482.05
2,153.29
35.09
322.30
0.22
41
112.87
63.73
49.14
726.95
453.45
10.20
#1 126.67
1
-97.69
77.41
80.26
159.86
-79.80
47.50
17.87
0
#1 2,300.00
78.05
61.90
145.74
-3.55
806.50
4.78
-56
20.99
-
15.45
22.30
33.09
84.00
5.00
2
-83.33
23.03
18.19
#9 12.89
#6 -0.97
#9 2.10
#9 -78.57
#7 -13
#9 -450.00
21.96
Growth Rate
Revenue Growth
-78.57 %
Net Income Growth
54.65 %
Cash Flow Change
-189.93 %
ROE
429.50 %
ROCE
193.29 %
EBITDA Margin (Avg.)
-1,484.07 %

Quarterly Financial Results

Quarterly Financials
Dec 2021
Mar 2022
Dec 2022
Mar 2023
Revenue
0
5
3
1
Expenses
0
2
3
2
EBITDA
0
2
-1
-1
Operating Profit %
0 %
46 %
-20 %
-206 %
Depreciation
0
1
1
0
Interest
0
1
3
1
Profit Before Tax
0
1
-4
-2
Tax
0
0
-2
-0
Net Profit
0
0
-3
-1
EPS in ₹
0.00
0.11
-4.06
0.00

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
2025
Total Assets
39
49
70
81
85
85
86
Fixed Assets
18
21
29
36
57
54
56
Current Assets
17
20
20
15
15
17
15
Capital Work in Progress
4
7
19
29
11
13
14
Investments
2
0
0
0
0
0
0
Other Assets
16
21
21
17
17
19
17
Total Equity & Liabilities
39
49
70
81
85
85
86
Current Liabilities
3
10
15
18
18
23
27
Non Current Liabilities
13
14
29
34
48
50
56
Total Equity
23
25
26
29
19
13
4
Reserve & Surplus
16
17
18
18
11
9
4
Share Capital
6
6
6
6
6
6
6

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
3
-3
3
-2
-0
0
0
Investing Activities
-6
-8
-22
-17
-6
-3
-7
Operating Activities
-1
2
7
5
-1
3
-2
Financing Activities
10
2
18
10
6
1
9

Share Holding

% Holding
Mar 2021
Sept 2021
Mar 2022
Sept 2022
Mar 2023
Sept 2023
Mar 2024
Sept 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
69.11 %
69.00 %
69.00 %
69.36 %
69.36 %
69.36 %
69.36 %
69.36 %
69.36 %
72.81 %
72.81 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
26.39 %
26.41 %
26.35 %
26.56 %
26.77 %
26.77 %
25.97 %
26.55 %
26.35 %
23.39 %
23.66 %
Others
4.50 %
4.59 %
4.65 %
4.08 %
3.87 %
3.87 %
4.67 %
4.09 %
4.29 %
3.81 %
3.53 %
No of Share Holders
361
412
409
393
394
388
418
424
408
408
419

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 46.70 50.99
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 48.02 43.34
04 Jan 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
04 Jan 2025 43.50 42.21
01 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
01 Aug 2025 23.85 28.29
30 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2025 23.11 24.26
14 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2025 27.60 26.22

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 201810 days ago
Closure of Trading WindowMar 24, 2026
Clarification On Movement In PriceMar 11, 2026
Clarification sought from Vanta Bioscience LtdFeb 25, 2026
Board Meeting Outcome for Outcome Of The Board Meeting - Appointment Of Company Secretary And Compliance OfficerJan 30, 2026
Financial Results For The Half Year Ended September 30 2025Nov 14, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14 2025Nov 14, 2025
Board Meeting Intimation for Board Meeting To Be Held On 14.11.2025Nov 08, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerNov 01, 2025
Reg. 34 (1) Annual Report.Nov 01, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 03, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Closure of Trading WindowSep 30, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2025Sep 06, 2025
Financials For The Half Year And Year Ended 31.03.2025Aug 01, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 01.08.2025Aug 01, 2025
Board Meeting Intimation for Postponement Of Board Meeting To August 01 2025Jul 29, 2025
Board Meeting Intimation for Postponement Of Board Meeting To July 29 2025Jul 26, 2025
Board Meeting Intimation for Postponement Of Board Meeting Scheduled On July 19 2025 And Will Now Be Held On Thursday July 24 2025Jul 19, 2025
Board Meeting Intimation for Board Meeting To Be Held On July 19 2025Jul 16, 2025
Rejection Of Promoter Reclassification ApplicationJun 16, 2025
Cancellation of Board MeetingMay 29, 2025
Results-Delay in Financial ResultsMay 29, 2025
Board Meeting Intimation for Board Meeting On 30/05/2025May 21, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011May 09, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.05.2025May 06, 2025
Intimation Regarding Receipt Of GLP Re-Certification For The Facility Of The Company In Gummidipundi Tamil NaduMay 02, 2025
Closure of Trading WindowMar 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 07, 2025
Notice Of EGM To Be Held On 04.01.2025Dec 12, 2024
EGM On 04.01.2025Dec 07, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.12.2024Dec 06, 2024
Board Meeting Intimation for Conversion Of Unsecured Loans Into Equity SharesDec 03, 2024
Unaudited Results For 30.09.2024Nov 14, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 14.11.2024Nov 14, 2024
Board Meeting Intimation for Approval Of Un-Audited Financial Statements Of 30.09.2024 And Conversion Of Unsecured Loans Into Equity SharesNov 11, 2024
Reply To Clarification On Price Movement Sought By BSENov 07, 2024
Clarification sought from Vanta Bioscience LtdNov 06, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 28, 2024
Submission Of Revised Financial Statements For The Period Ended 31.03.2024 Pursuant To Query From BSE Regarding Bifurcation Of Trade PayablesSep 19, 2024
Reg. 34 (1) Annual Report.Sep 06, 2024
AGM On 30.09.2024Sep 06, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2024 - 8Th Annual General Meeting To Be Held On 30.09.2024Sep 06, 2024
Intimation Of Submission Of Application To BSE For Reclassification From 'Promoter' Category To 'Public' CategoryAug 18, 2024
Regulation 30 - Submission Of Resignation Letters Of Directors Dated 19.07.2024Jul 24, 2024
Approval Of Board For Reclassification Of 2 Promoters To Public CategoryJul 20, 2024
Approval Of Board For Reclassification Of 2 Promoters To Public CategoryJul 20, 2024
Results For The Period Ended 31.03.2024Jul 19, 2024

Technical Indicators

RSI(14)
Neutral
51.00
ATR(14)
Less Volatile
1.92
STOCH(9,6)
Neutral
40.18
STOCH RSI(14)
Overbought
80.33
MACD(12,26)
Bullish
0.23
ADX(14)
Strong Trend
26.96
UO(9)
Bearish
44.51
ROC(12)
Uptrend And Accelerating
4.60
WillR(14)
Overbought
-16.71